Analysts Offer Insights on Healthcare Companies: Viracta Therapeutics (VIRX) and UnitedHealth (UNH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viracta Therapeutics (VIRX – Research Report) and UnitedHealth (UNH – Research Report) with bullish sentiments.

Viracta Therapeutics (VIRX)

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Viracta Therapeutics, with a price target of $13.00. The company’s shares closed last Tuesday at $0.71, close to its 52-week low of $0.43.

According to TipRanks.com, Singh is a 5-star analyst with an average return of 10.9% and a 43.9% success rate. Singh covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, Vertex Pharmaceuticals, and Oncternal Therapeutics.

Viracta Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.00, implying an 805.6% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

UnitedHealth (UNH)

Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on UnitedHealth today and set a price target of $610.00. The company’s shares closed last Tuesday at $468.89.

According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 15.3% and a 67.3% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as The Ensign Group, Community Health, and HCA Healthcare.

UnitedHealth has an analyst consensus of Strong Buy, with a price target consensus of $573.18, representing a 20.2% upside. In a report released today, Bank of America Securities also maintained a Buy rating on the stock with a $675.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VIRX:

• Viracta Therapeutics announces Nana-val results from stage 1 NAVAL-1 trial
• Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
• Viracta Therapeutics CFO Resigns, Interim Successor Appointed
• Viracta Therapeutics reports Q4 EPS (35c), consensus (31c)
• Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update